Correction to: New trends in cannabis potency in USA and Europe during the last decade (2008–2017) (European Archives of Psychiatry and Clinical Neuroscience, (2019), 269, 1, (5-15), 10.1007/s00406-019-00983-5);New trends in cannabis potency in USA and Europe during the last decade (2008–2017)

European Archives of Psychiatry and Clinical Neuroscience

Volumn 269, Issue 1, 2019, Pages 5-15

  Chandra, Suman ^a   Radwan, Mohamed M ^a   Majumdar, Chandrani G ^a   Church, James C ^b   Freeman, Tom P ^c,d   ElSohly, Mahmoud A ^a,e  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF WEST GEORGIA   (United States)

^c University of Bath   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Cannabis; CBD; CBG; CBN; Concentrates; Hash oil; Hashish; Marijunna; Potency monitoring; Sinsemilla; 9 THC

Indexed keywords

CANNABICHROMENE; CANNABIDIOL; CANNABIGEROL; CANNABINOID; CANNABIS; DRONABINOL; HERBACEOUS AGENT; CANNABINOID RECEPTOR AGONIST; STREET DRUG;

ARTICLE; DRUG POTENCY; EUROPE; HUMAN; LEGAL ASPECT; NATIONAL HEALTH ORGANIZATION; NETHERLANDS; PRIORITY JOURNAL; RECREATION; UNITED KINGDOM; UNITED STATES; CHEMISTRY; CLASSIFICATION; DRUG MONITORING; GAS CHROMATOGRAPHY;

CANNABINOID RECEPTOR AGONISTS; CANNABIS; CHROMATOGRAPHY, GAS; DRONABINOL; DRUG MONITORING; EUROPE; HUMANS; STREET DRUGS; UNITED STATES;

EID: 85060538381     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-019-01020-1     Document Type: Erratum

References (60)

1. Mukherjee A, Roy SC, De Bera S, Jiang H-E, Li X, Li C-S, Bera S (2008) Results of molecular analysis of an archaeological hemp (Cannabis sativa L.) DNA sample from North West China. Genet Resour Crop Evol 55:481–485
2. Russo EB (2007) History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers 4:1614–1648
3. Zuardi AW (2006) History of cannabis as a medicine: a review. Revista Brasileira de Psiquiatría 28:153–157
4. Aggarwal SK, Carter GT, Sullivan MD, ZumBrunnen C, Morrill R, Mayer JD (2009) Medicinal use of cannabis in the united states: historical perspectives, current trends, and future directions. J Opioid Manag 5:153–168
5. Kalant H (2001) Medicinal use of cannabis: History and current status. Pain Res Manag 6:80–91
6. Hanuš LO (2009) Pharmacological and therapeutic secrets of plant and brain (endo) cannabinoids. Med Res Rev 29:213–271
7. Sharma HK (1996) Sociocultural perspective of substance use in India. Subst Use Misuse 31:1689–1714
8. Mary Lynn Mathre R (2012) Cannabis in medical practice: a legal, historical and pharmacological overview of the therapeutic use of marijuana. McFarland, Jefferson
9. Fankhauser M (2002) History of cannabis in western medicine. The Haworth Integrative Healing Press, New York
10. Nunn JF (2002) Ancient Egyptian medicine. University of Oklahoma Press, Norman
11. Wills S (2003) Cannabis use and abuse by man: an historical perspective. In: Brown DT (ed) Cannabis. CRC Press, Boca Raton, pp 16–46
12. Booth M (2003) Cannabis: a history. St. Martin’s, New York
13. Du Toit BM (1980) Cannabis in Africa: A survey of its distribution in Africa, and a study of cannabis use and users in multi-ethnic South Africa. AA Bolkema, Rotterdam
14. Du Toit BM (1975) Dagga: the history and ethnographic setting of Cannabis sativa in Southern Africa. In: Rubin V (ed) Cannabis and culture. Mouton Publishers, The Hague, Paris, pp 81–116
15. Du Toit BM (1976) Man and cannabis in Africa: a study of diffusion. Afr Econ Hist 1:17–35
16. Laniel L (2006) Producing cannabis in Africa south of the Sahara: a review of OGD findings in the 1990s. In: Paper delivered at the international workshop, drugs and alcohol in Africa: production, distribution, consumption & control, St Antony’s College, University of Oxford
17. Parsche F, Balabanova S, Pirsig W (1993) Drugs in ancient populations. Lancet 341:503
18. Moore N, Brothwell D, Spigelman M, Parsche F (1993) Drugs in ancient populations. Lancet 341:1157
19. Assunção MR (1995) Popular culture and regional society in nineteenth-century Maranhgo, Brazil. Bull Latin Am Res 14:265–286
20. Marijuana EA (1980) The first 12,000 years. Plenum Press, New York
21. Courtwright DT (2001) Forces of habit: drugs and the making of the modern world. Harvard University Press, Cambridge
22. Amar MB (2006) Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol 105:1–25
23. Brown DT (ed) (2003) The therapeutic potential for cannabis and its derivatives. In: Cannabis. CRC Press, Boca Raton, pp 201–250
24. Hall W, Lynskey M (2016) Why it is probably too soon to assess the public health effects of legalisation of recreational cannabis use in the USA. Lancet Psychiatry 3:900–906
25. Hanuš LO, Meyer SM, Muñoz E, Taglialatela-Scafati O, Appendino G (2016) Phytocannabinoids: a unified critical inventory. Nat Prod Rep 33:1357–1392
26. Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJ, Parsons LH (2016) Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci 17:293–306
27. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, Nosarti C, MO’Carroll C, Seal M, Allen P (2010) Opposite effects of δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35:764–774
28. Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, Stone JM, Reichenberg A, Brenneisen R, Holt D (2013) Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol (Oxf) 27:19–27
29. Morgan CJ, Freeman TP, Schafer GL, Curran HV (2010) Cannabidiol attenuates the appetitive effects of δ9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology 35:1879–1885
30. Boggs DL, Nguyen JD, Morgenson D, Taffe MA, Ranganathan M (2018) Clinical and preclinical evidence for functional interactions of cannabidiol and δ 9-tetrahydrocannabinol. Neuropsychopharmacology 43:142
31. Colizzi M, Bhattacharyya S (2017) Does cannabis composition matter? Differential effects of delta-9-tetrahydrocannabinol and cannabidiol on human cognition. Curr Addict Rep 4:62–74
32. Englund A, Freeman TP, Murray RM, McGuire P (2017) Can we make cannabis safer? Lancet Psychiatry 4:643–648
33. Freeman TP, Morgan CJA, Hindocha C, Schafer GL, Das RK, Curran HV (2014) Just say ‘know’: how do cannabinoid concentrations influence users’ estimates of cannabis potency and the amount they roll in joints? Addiction 109:1686–1694
34. van der Pol P, Liebregts N, Brunt T, Amsterdam J, Graaf R, Korf DJ, Brink W, Laar M (2014) Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study. Addiction 109:1101–1109
35. Bidwelll LC, YorkWilliams SL, Mueller R, Bryan AD, Hutchison KE (2018) Exploring cannabis concentrates on the legal market: user profiles, product strength, and health-related outcomes. Addict Behav Rep 8:102–106
36. Freeman TP, Winstock AR (2015) Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med 45:3181–3189
37. Meier MH (2017) Associations between butane hash oil use and cannabis-related problems. Drug Alcohol Depend 179:25–31
38. Freeman TP, van der Pol P, Kuijpers W, Wisselink J, Das RK, Rigter S, van Laar M, Griffiths P, Swift W, Niesink R (2018) Changes in cannabis potency and first-time admissions to drug treatment: a 16-year study in The Netherlands. Psychol Med 48:2346–2352
39. Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, Bianconi F, Gardner-Sood P, O’Connor J, Russo M (2015) Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2:233–238
40. Schoeler T, Petros N, Di Forti M, Klamerus E, Foglia E, Ajnakina O, Gayer-Anderson C, Colizzi M, Quattrone D, Behlke I (2016) Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study. Lancet Psychiatry 3:947–953
41. Wilson J, Freeman TP, Mackie CJ (2018) Effects of increasing cannabis potency on adolescent health. Lancet Child Adolesc Health. 10.1016/S2352-4642(1018)30342-30340
42. Smart R, Caulkins JP, Kilmer B, Davenport S, Midgette G (2017) Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state. Addiction 112:2167–2177
43. Freeman T, Swift W (2016) Cannabis potency: the need for global monitoring. Addiction 111:376–377
44. ElSohly MA, Ross SA, Mehmedic Z, Arafat R, Yi B, Banahan BF 3rd (2000) Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980 to 1997. J Forensic Sci 45:24–30
45. Mehmedic Z, Chandra S, Slade D, Denham H, Foster S, Patel AS, Ross SA, Khan IA, ElSohly MA (2010) Potency trends of delta9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 55:1209–1217
46. Slade D, Mehmedic Z, Chandra S, ElSohly MA (2011) Is Cannabis becoming more potent? In: Castle DJ, Murray RM, D’Souza DC (eds) Marijuana and Madness, 2nd Edition. Cambridge University Press, Cambridge, pp 35–54
47. ElSohly M, Holley J, Turner C (1985) Constituents of cannabis sativa l. XXVI. The delta-9-tetrahydrocannabinol content of confiscated marijuana, 1974–1983. In: Marihuana’84: proceedings of the Oxford symposium on cannabis: 9th international congress of pharmacology, 3rd satellite symposium on cannabis/edited by D.J. Harvey; assistant editors Sir William Paton, GG Nahas. IRL Press, Oxford, c1985
48. ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC (2016) Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the united states. Biol Psychiatry 79:613–619
49. Ross S, ElSohly M (1997) CBN and∆ 9-THC concentration ratio as an indicator of the age of stored marijuana samples. Bull Narc 49:139–139
50. Cascini F, Aiello C, Di Tanna G (2012) Increasing delta-9-tetrahydrocannabinol (δ-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev 5:32–40
51. Freeman TP, Groshkova T, Cunningham A, Sedefov R, Griffiths P, Lynskey MT (2019) Increasing potency and price of cannabis in Europe, 2006–2016. Addiction (in press)
52. Chouvy P-A, Afsahi K (2014) Hashish revival in morocco. Int J Drug Policy 25:416–423
53. Pijlman F, Rigter S, Hoek J, Goldschmidt H, Niesink R (2005) Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. Addict Biol 10:171–180
54. 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci 53:90–94
55. Hardwick S, King LA (2008) Home office cannabis potency study 2008. Home Office Scientific Development Branch, St Albans
56. Potter DJ, Hammond K, Tuffnell S, Walker C, Di Forti M (2018) Potency of δ9-tetrahydrocannabinol and other cannabinoids in cannabis in England in 2016: implications for public health and pharmacology. Drug Test Anal 10:628–635
57. Zamengo L, Frison G, Bettin C, Sciarrone R (2014) Understanding the risks associated with the use of new psychoactive substances (NPS): high variability of active ingredients concentration, mislabelled preparations, multiple psychoactive substances in single products. Toxicol Lett 229:220–228
58. Zamengo L, Frison G, Bettin C, Sciarrone R (2015) Cannabis potency in the Venice area (Italy): update 2013. Drug Test Anal 7:255–258
59. Dujourdy L, Besacier F (2017) A study of cannabis potency in France over a 25 years period (1992–2016). Forensic Sc Int 272:72–80
60. Hillig KW, Mahlberg PG (2004) A chemotaxonomic analysis of cannabinoid variation in cannabis (Cannabaceae). Am J Bot 91:966–975